Xeris Biopharma Holdings (XERS) Total Debt (2023 - 2026)

Xeris Biopharma Holdings has reported Total Debt for 4 years, with the latest figure at $221.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt fell 3.72% year-over-year to $221.2 million; the trailing twelve-month figure through Mar 2026 stood at $221.2 million (down 3.72% YoY), and the FY2025 full-year result was $220.3 million, down 5.07% from the prior year.
• Total Debt for Q1 2026 stood at $221.2 million, roughly flat from $220.3 million in the prior quarter.
• The five-year high for Total Debt was $232.1 million in Q4 2024, with the low at $420000.0 in Q2 2024.
• Historically, Total Debt has averaged $131.9 million across 4 years, with a median of $204.8 million in 2023.
• Annual changes were most pronounced in 2024 — Total Debt plunged 97.48% — and 2025, when it jumped 51953.81%.
• Xeris Biopharma Holdings' Total Debt stood at $190.9 million in 2023, then gained by 21.57% to $232.1 million in 2024, then declined by 5.07% to $220.3 million in 2025, then advanced by 0.4% to $221.2 million in 2026.
• The last three Total Debt figures came in at $221.2 million (Q1 2026), $220.3 million (Q4 2025), and $219.5 million (Q3 2025), per Business Quant data.